APA

Braegelmann C., Hölzel M., Ludbrook V., Dickson M., Turan N., Ferring-Schmitt S., Sternberg S., Bieber T., Kuhn A. & Wenzel J. (20180129). Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. : Experimental dermatology.

Chicago

Braegelmann Christine, Hölzel Michael, Ludbrook Valerie, Dickson Marion, Turan Nil, Ferring-Schmitt Sandra, Sternberg Sonja, Bieber Thomas, Kuhn Annegret and Wenzel Joerg. 20180129. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. : Experimental dermatology.

Harvard

Braegelmann C., Hölzel M., Ludbrook V., Dickson M., Turan N., Ferring-Schmitt S., Sternberg S., Bieber T., Kuhn A. and Wenzel J. (20180129). Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. : Experimental dermatology.

MLA

Braegelmann Christine, Hölzel Michael, Ludbrook Valerie, Dickson Marion, Turan Nil, Ferring-Schmitt Sandra, Sternberg Sonja, Bieber Thomas, Kuhn Annegret and Wenzel Joerg. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. : Experimental dermatology. 20180129.